| NCT06245213 | A Study of ANAVEX3-71 in Adults With Schizophrenia | ACTIVE_NOT_RECRUITING | PHASE2 | 2024-03-15 | 2025-06-30 | 2025-06-30 |
| NCT04442945 | Phase 1 Study of ANAVEX3-71 | COMPLETED | PHASE1 | 2020-07-03 | 2021-10-30 | 2021-09-30 |
| NCT04304482 | ANAVEX2-73 Study in Pediatric Patients With Rett Syndrome | COMPLETED | PHASE2, PHASE3 | 2020-07-01 | 2023-06-30 | 2023-06-01 |
| NCT04314934 | OLE of Phase 2b/3 Study ANAVEX2-73-AD-004 | COMPLETED | PHASE2, PHASE3 | 2019-10-10 | 2024-06-14 | 2024-06-14 |
| NCT04575259 | OLE Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001 | COMPLETED | PHASE2 | 2019-10-10 | 2022-06-30 | 2022-05-31 |
| NCT03941444 | ANAVEX2-73 Study in Patients With Rett Syndrome | COMPLETED | PHASE3 | 2019-05-06 | 2021-09-30 | 2021-09-30 |
| NCT03758924 | Study of ANAVEX2-73 in Patients With Rett Syndrome | COMPLETED | PHASE2 | 2019-02-28 | 2020-10-30 | 2020-10-30 |
| NCT03774459 | ANAVEX2-73 Study in Parkinson's Disease Dementia | COMPLETED | PHASE2 | 2018-07-09 | 2020-09-30 | 2020-09-30 |
| NCT03790709 | ANAVEX2-73 for Treatment of Early Alzheimer's Disease | COMPLETED | PHASE2, PHASE3 | 2018-07-03 | 2022-06-30 | 2022-06-30 |
| NCT02756858 | An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease | COMPLETED | PHASE2 | 2016-03 | 2020-11 | 2020-11 |
| NCT02244541 | Phase 2a Dose Finding, PK/PD and 12 Month Exploratory Efficacy Study of ANAVEX2-73 in Patients With Alzheimer's Disease | COMPLETED | PHASE2 | 2014-12 | 2016-11 | 2015-11 |